Co-Diagnostics, Inc. (CODX) Q3 2025 Earnings Call Summary

1Key Financial Results and Metrics

Total Revenue: $0.1 million, down from $0.6 million in Q3 2024. The previous year included $0.4 million from grants, while current revenue was solely from product sales.

Operating Expenses: Decreased to $7.1 million from $10.6 million in the prior year, reflecting improved operational efficiency.

Net Loss: $5.9 million, or $0.16 per diluted share, compared to a loss of $9.7 million, or $0.32 per diluted share in Q3 2024.

Adjusted EBITDA: Loss of $6.3 million, improved from a loss of $8.8 million in the same period last year.

Cash Position: Ended the quarter with $11.4 million in cash, cash equivalents, and marketable securities.

2Strategic Updates and Business Highlights

Growth Pillars: Co-Diagnostics is focusing on four main growth areas:

CoSara SPAC Transaction: Engaging Maxim Group to explore strategic alternatives for the Indian joint venture, potentially unlocking value and providing growth capital.

CoMira Joint Venture: Established with Arabian Eagle to expand operations in Saudi Arabia and 18 other MENA countries, focusing on localizing the Co-Dx PCR platform.

AI Business Unit: Launched to drive innovation and operational efficiency, integrating AI into diagnostics and data analytics.

Clinical Evaluations: Preparing to initiate clinical evaluations for an upper respiratory multiplex test, supported by a RADx Tech grant from the NIH.

3Forward Guidance and Outlook

Co-Diagnostics anticipates multiple commercial launches in 2026, driven by ongoing development within its test pipeline and strategic partnerships.

The company is optimistic about its financial position and growth potential, supported by recent fundraising efforts totaling $10.8 million.

4Bad News, Challenges, or Points of Concern

Revenue Decline: A significant drop in revenue compared to the previous year raises concerns about sales performance and market demand.

Net Loss: Continued losses indicate ongoing financial challenges, although the company is focused on improving operational efficiencies.

Regulatory Approval: The success of the Co-Dx PCR platform and other products hinges on obtaining necessary regulatory approvals, which poses a risk to timelines and commercialization efforts.

5Notable Q&A Insights

Performance of CoSara and CoMira: Management expressed satisfaction with both entities, highlighting CoMira's potential due to its established distributor relationships in Saudi Arabia. CoSara is seen as a mature business capable of filling significant market gaps in India.

Affordability of PCR Pro: The company aims to offer competitive pricing for its PCR Pro device, leveraging innovative engineering and the use of Co-Primers to achieve lower production costs.

Market Relevance: The upper respiratory multiplex test is highlighted as particularly relevant for the MENA market, alongside tuberculosis and HPV tests, indicating a broad product applicability in the region. Overall, Co-Diagnostics is navigating a challenging financial landscape while pursuing strategic initiatives aimed at long-term growth and market expansion.